Pdia1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
---
title: PDIA1 Protein
---
[^4]
[^5]
[^6]
[^7]
| Protein Disulfide Isomerase (PDI) |
|---|
| Protein Name | Protein Disulfide Isomerase (PDI) |
| Gene | [PDIA1](/genes/pdia1) |
| UniProt ID | P07237 |
| PDB ID(s) | 3UQW, 4EL1, 5E84 |
| Molecular Weight | ~57 kDa |
| Subcellular Location | Endoplasmic Reticulum Lumen |
| Protein Family | Protein Disulfide Isomerase Family |
Protein Disulfide Isomerase (PDI), encoded by the PDIA1 gene (also known as P4HB), is the founding member of the protein disulfide isomerase family. As one of the most abundant chaperone proteins in the endoplasmic reticulum (ER), PDI plays a central role in protein folding and cellular proteostasis. The enzyme catalyzes the formation, rearrangement, and reduction of disulfide bonds—a critical post-translational modification that stabilizes the three-dimensional structure of secretory and membrane proteins.
PDI is a 508-amino acid ER-resident protein that belongs to the thioredoxin superfamily. The protein possesses a characteristic multi-domain architecture consisting of:
- a domain (N-terminal thioredoxin-like catalytic domain): Contains the active site Cys-Gly-His-Cys (CGHC) motif
- b domain (C-terminal thioredoxin-like substrate-binding domain): Recognizes client proteins
- a' domain (C-terminal thioredoxin-like domain): Additional catalytic activity
- b' domain (central substrate-binding domain): Binds hydrophobic peptide sequences
- c domain (C-terminal extension): Contains the KDEL ER retention signal
This modular structure enables PDI to simultaneously recognize diverse substrate proteins while catalyzing disulfide bond formation through its dual active sites.
PDI undergoes cyclic oxidation and reduction during its catalytic cycle:
- Oxidized PDI (disulfide bonds in active site) transfers its disulfides to substrate proteins
- Reduced PDI (thiols in active site) accepts disulfides from substrate proteins
- The oxidized PDI is then regenerated by the ER oxidoreductase ERO1α
The three-dimensional structure of PDI has been resolved by X-ray crystallography and cryo-EM, revealing:
- A horseshoe-shaped arrangement of the thioredoxin domains
- A flexible linker between the b and b' domains allowing substrate access
- A substrate-binding pocket formed by the b' domain that recognizes hydrophobic sequences
- Dimerization through the a' domain, creating a larger substrate-binding surface
Crystal structures (PDB: 3UQW, 4EL1, 5E84) show the domain organization and have informed drug discovery efforts targeting PDI.
PDI exhibits multiple enzymatic activities essential for protein folding:
- Oxidoreductase activity: Catalyzes disulfide bond formation and reduction
- Isomerase activity: Rearranges incorrect disulfide bonds to the correct connectivity
- Chaperone activity: Prevents aggregation through binding of hydrophobic patches
PDI participates in multiple aspects of ER quality control:
- Folding assistance: Accelerates correct protein folding
- ER-associated degradation (ERAD): Recognizes misfolded proteins for degradation
- Redox regulation: Maintains the ER redox environment optimal for folding
PDI interacts with numerous client proteins and partner proteins:
- ERO1α: ER oxidoreductase that reoxidizes PDI
- ERp57: PDI family member that cooperates in glycoprotein folding
- ERp72: PDI family member with overlapping function
- Calnexin/Calreticulin: ER chaperones in the glycoprotein folding pathway
In Alzheimer's disease (AD), PDI is implicated through its role in ER stress response:
- Aβ peptides induce ER stress in neurons
- PDI expression is upregulated as an adaptive response
- Chronic ER stress leads to PDI dysfunction and neuronal apoptosis
- PDI can interact with Aβ, potentially influencing its aggregation
PDI involvement in Parkinson's disease (PD) centers on alpha-synuclein handling:
- Alpha-synuclein aggregation induces ER stress
- PDI upregulation observed in PD substantia nigra
- PDI may interact with alpha-synuclein and modulate its toxicity
- ER stress-mediated dopaminergic neuron death involves PDI dysregulation
PDI plays roles in:
- Amyotrophic Lateral Sclerosis (ALS): SOD1 and TDP-43 mutations cause ER stress
- Huntington's Disease: Polyglutamine expansions induce ER stress
- Prion Diseases: Prion protein misfolding triggers UPR
PDI represents a promising therapeutic target for neurodegenerative diseases:
- PDI inhibitors: Compound 16, 1,4-benzodiazepine derivatives
- Allosteric modulators: Molecules targeting non-active site regions
- ER stress modulators: Drugs enhancing adaptive UPR signaling
- Proteostasis enhancers: Compounds boosting overall protein folding capacity
- PDIA1 overexpression: Enhancing ER folding capacity
- Redox modulators: Balancing ER redox environment
- Protein disulfide isomerase: a promising therapeutic target for neurodegenerative diseases - PMID: 37928765
- The role of protein disulfide isomerase in Alzheimer's disease - PMID: 35193542
- Structure and function of protein disulfide isomerase - PMID: 12446006
- PDI protects neurons from ER stress-induced apoptosis - PMID: 19641619
- Upregulation of PDIA1 in Parkinson's disease brain - PMID: 25392304